Refinement of an Autocidal Gravid Ovitrap for mass-manufacturing

 描述(申请人提供)：致命诱卵器是一种常见蚊子种群监测技术的改进：成年雌性蚊子被引诱到一个水容器产卵，并暴露在致命剂量的杀虫剂中。自杀妊娠诱卵器(AGO)在几个方面改进了这项技术。它已被修改，使其对怀孕的埃及伊蚊更具吸引力。杀灭剂是一种粘合剂，因此延长了有用的田间寿命，同时消除了对杀虫剂的需求。该项目旨在对现有的AGO设计进行修改，使其适合批量生产。我们的目标是生产一种有效、成本效益高和耐用的 很久以前了。长期目标包括优化利用AGO来控制携带虫媒病毒的蚊子，以防止登革热和其他疾病的爆发，并将该技术推广到其他集装箱繁殖的蚊子物种。预计最终结果将是一种商业上可行的产品，可供专业和家庭使用。第一阶段的努力最终在AGO的原型注塑模具中达到顶峰，设计的各个元素通过数字和竞争性笼式生物检测进行了验证。评估了多种合成引诱剂，其中几种的表现至少与标准的干草浸泡一样好。一期AGO适合批量生产，性价比高，使用方便，对Ae具有很强的吸引力。埃及伊蚊。第二阶段将产生一种可以大规模生产的产品，该产品对集装箱滋生的蚊子具有证明的有效性。注射成型的AGO将在大空间和现场测试中进行有效性和耐用性评估。引诱剂配方将在竞技场和田间试验中得到提炼，至少与干草浸泡一样吸引人，并且易于包装和运输。将扩大大规模的城市实地测试，以测试AGO在抑制这两种疾病方面的有效性。Aegypti和Ae.白纹伊蚊。美国疾病控制与预防中心开发的诊断“快速测试”将用于确定被困蚊子的患病频率，以评估大规模部署AGO是否会将蚊子数量降至登革热传播门槛以下。容器滋生蚊子，如Ae。Aegypti和Ae.白纹伊蚊是一种白天叮咬的蚊子。它们也是严重病毒性疾病的媒介，包括登革热、黄热病和基孔肯雅热。目前，热带国家有25亿人面临感染登革热的风险。CDC-NCEZID的任务是检测、预防和控制人畜共患传染病。登革热和基孔肯雅热目前并不是美国居民面临的主要威胁，但随着蚊子媒介范围的扩大，这些疾病正在传播。AGO既是控制这些日益入侵的物种传播的监测工具，也是通过在整个区域范围内抑制蚊子种群而用于暴发的有效控制选择。它有望成为控制蚊子滋扰的长期战斗中的重要工具，改善受影响地区人民的生活质量，并预防媒介传播疾病。

 DESCRIPTION (provided by applicant): Lethal ovitraps are a modification of a common mosquito population monitoring technology: adult females are enticed to a water container to lay their eggs and are exposed to a lethal dose of pesticide. The Autocidal Gravid Ovitrap (AGO) improves this technology in several ways. It has been modified to make it more attractive to gravid Aedes aegypti. The killing agent is an adhesive, thus extending the useful field life while negating the need for insecticides. This project aims to modify the current AGO design to make it suitable for mass production. The goal is to produce an efficacious, cost-effective, and durable AGO. Long-term objectives include optimizing use of the AGO for control of arbovirus-vectoring mosquitoes to prevent outbreaks of dengue and other diseases, and extending the technology for use with other container-breeding species of mosquitoes. The final result is expected to be a commercially viable product for professional and home use. Phase I efforts culminated in a prototype injection mold for the AGO, with individual elements of the design validated both digitally and in competitive cage bioassays. Multiple synthetic attractants were evaluated, with several performing at least as well as the standard hay infusion. The Phase I AGO is suitable for mass production, cost-effective, user-friendly, and has high attraction to Ae. aegypti. Phase II will result in a product that can be mass-manufactured with demonstrated efficacy against container- breeding mosquitoes. The injection-molded AGO will be evaluated in large room and field tests for effectiveness and durability. The attractant formulation will be refined in arena ad field tests to be at least as attractive as hay infusion, and easily packaged and shipped. Large-scale urban field testing will be expanded to test the AGO's efficacy in suppressing both Ae. aegypti and Ae. albopictus. A CDC-developed diagnostic "quick test" will be used to determine disease frequency in trapped mosquitoes, to assess if large-scale deployment of the AGO reduces the mosquito population below the dengue transmission threshold. Container-breeding mosquitoes such as Ae. aegypti and Ae. albopictus are day-biting nuisance mosquitoes. They are also vectors of serious viral diseases, including dengue fever, yellow fever, and chikungunya. Currently >2.5 billion people in tropical countries are at risk of infection with dengue fever. The mission of the CDC-NCEZID is to detect, prevent, and control zoonotic infectious diseases. Dengue fever and chikungunya are not currently major threats to US residents, but these diseases are spreading as their mosquito vectors expand their ranges. The AGO will be both a monitoring tool to check the spread of these increasingly invasive species, and an effective control option for use in outbreaks by creating area-wide suppression of mosquito populations. It promises to be an important tool in the long term battle to control nuisance mosquitoes, improve quality of life for people in affected areas, and prevent vector-borne diseases.